- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TENECTEPLASE VERSUS ALTEPLASE IN STROKE PATIENTS WITH LARGE VESSEL OCCLUSION: RESULTS FROM THE ACT TRIAL (Hall 406) - Oct 1, 2022 - Abstract #WSC2022WSC_304;
Increased reperfusion with TNK persists across the spectrum of thrombolytic-to-initial-angiographic-assessment times. Intravenous tenecteplase has similar benefit as alteplase in patients with AIS and large vessel occlusions.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TENECTEPLASE VERSUS ALTEPLASE IN THE REAL WORLD: UPDATED NEW ZEALAND DATA (Nicoll 2-3) - Oct 1, 2022 - Abstract #WSC2022WSC_120;
Intravenous tenecteplase has similar benefit as alteplase in patients with AIS and large vessel occlusions. A forced reversion from Tenecteplase to Alteplase demonstrates that previously reported benefits from TNK in a real-world setting were not simply attributable to a concurrent temporal trend.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke. (Pubmed Central) - Sep 24, 2022
No significant differences were identified in mortality; 17.5% with rtPA and 20% with TNK (p = 0.79), nor in the appearance of intracranial hemorrhage ICH (15.2% with rtPA vs. 30% with TNK (p = 0.12). In our series, there were not significant differences shown regarding effectiveness and safety between tenecteplase and alteplase.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Observational data, Journal: Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice. (Pubmed Central) - Sep 24, 2022
Switching to tenecteplase in routine clinical practice in a 10-hospital network was associated with shorter door-to-needle time and door-in-door-out times, noninferior favorable clinical outcomes at discharge, and reduced hospital costs. Evaluation in larger, multicenter cohorts is recommended to determine if these observations generalize.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Treatments in Ischemic Stroke: Current and Future. (Pubmed Central) - Sep 24, 2022
The COVID-19 pandemic has critically stressed global healthcare systems, with collateral damage resulting in access delivery of only emergency care, such as ischemic stroke. Regarding telemedicine, it has had a minor role in acute stroke management, and with the onset of COVID-19, this role will most likely be adopted to increase access and delivery in stroke assessment, but also in the follow-up.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. (Pubmed Central) - Sep 23, 2022
This study shows that the suboptimal fibrinolytic response in COVID-19 disease is directly attributable to elevated levels of PAI-1, which attenuate plasmin generation. These data highlight the important prognostic potential of PAI-1 and the possibility of using pre-existing drugs, such as tenecteplase, to treat COVID-19 disease and potentially other respiratory diseases.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Sep 23, 2022
P3, N=1400, Recruiting,
These data highlight the important prognostic potential of PAI-1 and the possibility of using pre-existing drugs, such as tenecteplase, to treat COVID-19 disease and potentially other respiratory diseases. Active, not recruiting --> Recruiting | N=916 --> 1400 | Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment closed: STREAM-2: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction (clinicaltrials.gov) - Sep 22, 2022
P4, N=604, Active, not recruiting,
Active, not recruiting --> Recruiting | N=916 --> 1400 | Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023 Recruiting --> Active, not recruiting
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Risk stratification and in-hospital outcome in patients with acute coronary syndrome. (Pubmed Central) - Sep 21, 2022
There was a marked preponderance of STEMI in younger patients but it was less marked in older patients, according to the study. All conventional risk factors were represented in all types of ACS but hypertension and tobacco abuse were more consistent risk factors associated with STEMI.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Sep 16, 2022
P3, N=916, Active, not recruiting,
TNK is noninferior to ALT at the short term efficacy outcomes: early neurological improvement and recanalization. Recruiting --> Active, not recruiting
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion date, Trial primary completion date: TIMELESS: Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (clinicaltrials.gov) - Sep 6, 2022
P3, N=456, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2429;
Tenecteplase treatment was highly cost-effective for AIS patients due to LVO compared to alteplase treatment. The finding supports tenecteplase’s broader use in acute stroke care as health outcomes improve at acceptable costs, while having practical advantages, and a similar safety profile.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke. (Pubmed Central) - Aug 26, 2022
There was no significant difference in all-cause inpatient mortality for alteplase versus tenecteplase (10 [5%] vs 5 [4%], P = 0.934) or in adverse events between the groups (22 [9%] vs 14 [12%], P = 0.541) for alteplase and tenecteplase, respectively. Tenecteplase had similar rates of major bleeding versus alteplase and may be a reasonable alternative in the treatment of acute ischemic stroke.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: IV thrombolysis with tenecteplase for the treatment of acute ischemic stroke. (Pubmed Central) - Aug 24, 2022
IVT with tenecteplase was associated with better 3-month clinical outcomes compared to IVT with alteplase in AIS patients, with no increased risk of symptomatic intracranial bleeding. ANN NEUROL 2022;92:349-357.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: IV tenecteplase: A non-inferior alternative to alteplase? (Pubmed Central) - Aug 22, 2022
The standard medical therapy for intravenous thrombolysis in patients with stroke presenting within 3 h is alteplase, a tissue plasminogen activator. Menon and colleagues assessed the non-inferiority, efficacy, and safety of tenecteplase, a modified version of alteplase, in patients with acute ischemic stroke presenting within 4.5 h of onset.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future? (Pubmed Central) - Aug 17, 2022
Based on recent and upcoming trials, guidelines may soon recommend tenecteplase as a suitable alternative to alteplase. The use of tenecteplase in specific subgroups will depend on further recruitment to ongoing clinical trials.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Co2 Contrast: Problems Always Bubble Up (Hall C) - Aug 15, 2022 - Abstract #ASA2022ASA_4414;
After multiple episodes of recurrence only intermittently associated with relative hypotension tenecteplase was administered out of concern for thrombotic etiology that resulted in partial resolution. Follow up testing was inconclusive.
- |||||||||| Review: The Efficacy and Safety of Ischemic Stroke Therapies: An Umbrella Review. (Pubmed Central) - Aug 10, 2022
Our study demonstrated that tPA, edaravone and tPA, tPA and MTE, acupuncture and Western medicines, and blood-activating and stasis-dispelling herbs with Western medicines are the optimum neurological function and activities of daily living medication for patients with ischemic stroke. Systematic Review Registration: https://inplasy.com/, identifier [INPLASY202250145].
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Observational data, Review, Journal: Comparison of tenecteplase versus alteplase in STEMI patients treated with ticagrelor: A cross-sectional study. (Pubmed Central) - Jul 23, 2022
The administration of tenecteplase in STEMI patients who received a loading dose with ticagrelor resulted in a significant reduction in MACE compared to alteplase. Larger multi-center studies are warranted to investigate the effect of tenecteplase treatment on clinical results.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Head-to-Head: Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. (Pubmed Central) - Jul 23, 2022
P3
In safety analyses, 27 (3·4%) of 800 patients in the tenecteplase group and 24 (3·2%) of 763 in the alteplase group had 24 h symptomatic intracerebral haemorrhage and 122 (15·3%) of 796 and 117 (15·4%) of 763 died within 90 days of starting treatment Intravenous tenecteplase (0·25 mg/kg) is a reasonable alternative to alteplase for all patients presenting with acute ischaemic stroke who meet standard criteria for thrombolysis. Canadian Institutes of Health Research, Alberta Strategy for Patient Oriented Research Support Unit.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Tenecteplase for acute ischaemic stroke. (Pubmed Central) - Jul 23, 2022
Canadian Institutes of Health Research, Alberta Strategy for Patient Oriented Research Support Unit. No abstract available
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Ischaemic stroke and infectious endocarditis by Gemella Morbillorum: usefulness of mechanical thrombectomy for diagnosis (A7) - Jul 18, 2022 - Abstract #EAN2022EAN_1300;
Treatment involved thrombolysis with Tenecteplase, and mechanical thrombectomy with TICI 3; the thrombus was frozen for study...Treatment with Ceftriaxone 2g every 24h resulted in an excellent clinical evolution, with an mRS of 1 after 3 months... Histological study of thrombi can help identify the etiological mechanism of cryptogenic ischemic strokes, but the microbiological study of this material can also be key for diagnosis.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Investigational drugs for ischemic stroke: what's in the clinical development pipeline for acute phase and prevention? (Pubmed Central) - Jul 15, 2022
Regarding primary and secondary prevention, research is primarily focused on identifying mechanisms to improve the safety-efficacy profile using a "hemostasis-sparing" approach. Further evaluation on those agents that have already shown promise for their risk/benefit profiles, would benefit greatly a neurologist's capacity to successfully prevent and treat ischemic stroke patients.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal, Head-to-Head: Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. (Pubmed Central) - Jul 13, 2022
P3
We did not show non-inferiority of direct endovascular thrombectomy compared with bridging therapy. The additional information from our study should inform guidelines to recommend bridging therapy as standard treatment.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Preclinical, Journal: Impact of poly-arginine peptides R18D and R18 on alteplase and tenecteplase thrombolysis in vitro, and neuroprotective stability to proteolysis. (Pubmed Central) - Jul 10, 2022
In addition, the in vitro anti-excitotoxic neuroprotective efficacy of R18D and R18 was not affected by pre-incubation for 1-2 h or overnight with tPA or TNK, whereas only R18D retained high anti-excitotoxic neuroprotective efficacy when pre-incubated in a synthetic trypsin (TrypLE Express). The present in vitro findings suggest that neither R18D or R18 when co-administered with the thrombolytic inducing agents tPA or TNK are likely to have a significant impact when used clinically during clot thrombolysis and confirm the superior proteolytic stability of the R18D peptide.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Tenecteplase in Patients With COVID-19 (clinicaltrials.gov) - Jul 7, 2022
P2, N=13, Completed,
None. Enrolling by invitation --> Completed | N=60 --> 13 | Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism. (Pubmed Central) - Jul 6, 2022
Enrolling by invitation --> Completed | N=60 --> 13 | Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Oct 2021 --> Mar 2022 The proposed design allows evaluation of a greater number of dose levels than would be possible with a non-adaptive design and avoids the need to choose either the continuous or the dichotomized analysis strategy for the primary endpoint.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis. (Pubmed Central) - Jul 2, 2022
This meta-analysis indicated that tenecteplase in AIS patients is as safe and effective as alteplase and might provide more benefit than alteplase. However, due to several inherent limitations of this study, more prospective studies should be conducted to confirm the above results.
|
